User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

On glioblastoma and the search for a cure: where do we stand?

Primary tabs

Bianco, John [UCL] Bastiancich, Chiara [UCL] Jankovski, Aleksandar [UCL] des Rieux, Anne [UCL] Préat, Véronique [UCL] Danhier, Fabienne [UCL]

Although brain tumours have been documented and recorded since the nineteenth century, 2016 marked 90 years since Percival Bailey and Harvey Cushing coined the term "glioblastoma multiforme". Since that time, although extensive developments in diagnosis and treatment have been made, relatively little improvement on prognosis has been achieved. The resilience of GBM thus makes treating this tumour one of the biggest challenges currently faced by neuro-oncology. Aggressive and robust development, coupled with difficulties of complete resection, drug delivery and therapeutic resistance to treatment are some of the main issues that this nemesis presents today. Current treatments are far from satisfactory with poor prognosis, and focus on palliative management rather than curative intervention. However, therapeutic research leading to developments in novel treatment stratagems show promise in combating this disease. Here we present a review on GBM, looking at the history and advances which have shaped neurosurgery over the last century that cumulate to the present day management of GBM, while also exploring future perspectives in treatment options that could lead to new treatments on the road to a cure.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2017
Language Anglais
Journal information "Cellular and Molecular Life Sciences" - Vol. 74, no. 13, p. 2451-2466 (2017)
Peer reviewed yes
Publisher Springer ((Switzerland) Basel)
issn 1420-682X
e-issn 1420-9071
Publication status Publié
Affiliations UCL - SSS/LDRI - Louvain Drug Research Institute
UCL - SSS/IREC/MONT-Pôle Mont Godinne
UCL - (MGD) Service de neurochirurgie
UCL - SSS/IONS/NEUR - Clinical Neuroscience
Keywords Cancer stem cells ; Drug delivery ; Glioblastoma multiforme ; Therapeutic resistance
Links
  1. Jones Edward G., Golgi, Cajal and the Neuron Doctrine, 10.1076/jhin.8.2.170.1838
  2. Bock Ortwin, Cajal, Golgi, Nansen, Schäfer and the Neuron Doctrine, 10.1016/j.endeavour.2013.06.006
  3. DeAngelis Lisa M., Mellinghoff Ingo K., Virchow 2011 or How to ID(H) Human Glioblastoma, 10.1200/jco.2011.37.5873
  4. Scherer H (1940) A critical review: the pathology of cerebral gliomas. J Neurol. Psychiatry 3(2):147–177
  5. Barker Fred G., The Massachusetts General Hospital : Early history and neurosurgery to 1939, 10.3171/jns.1993.79.6.0948
  6. Lister J., On the Antiseptic Principle in the Practice of Surgery, 10.1136/bmj.2.351.246
  7. Kerr P. Benjamin, Caputy Anthony J., Horwitz Norman H., A history of cerebral localization, 10.3171/foc.2005.18.4.2
  8. Greenblatt Samuel H., The crucial decade: modern neurosurgery's definitive development in Harvey Cushing's early research and practice, 1900 to 1910, 10.3171/jns.1997.87.6.0964
  9. Macewen William, INTRA-CRANIAL LESIONS,, 10.1016/s0140-6736(02)36340-2
  10. Greenblatt S. H., A surgeon for the brain, 10.1093/brain/awl349
  11. Macewen W (1879) Tumour of the dura mater; convulsions; removal of tumour by trephining; recovery. Glasgow Med J 12:208–213
  12. Bennett A. Hughes, Godlee Rickman J., Case of Cerebral Tumour. The Surgical Treatment, 10.1177/095952878506800120
  13. Kirkpatrick Douglas B., The first primary brain-tumor operation, 10.3171/jns.1984.61.5.0809
  14. Greenblatt Samuel H., Harvey Cushing's Paradigmatic Contribution to Neurosurgery and the Evolution of His Thoughts about Specialization, 10.1353/bhm.2003.0168
  15. Horsley V., Remarks on Ten Consecutive Cases of Operations upon the Brain and Cranial Cavity to Illustrate the Details and Safety of the Method Employed, 10.1136/bmj.1.1373.863
  16. British Medical Association, 10.1136/bmj.2.1345.670
  17. Tan T, Black P (2002) Sir Victor Horsley (1857–1916): pioneer of neurological surgery. Neurosurgery 50(3):607–611
  18. Toledo-Pereyra Luis H., X-Rays Surgical Revolution, 10.1080/08941930903300054
  19. Voorhees Jennifer R., Cohen-Gadol Aaron A., Spencer Dennis D., Early evolution of neurological surgery: conquering increased intracranial pressure, infection, and blood loss, 10.3171/foc.2005.18.4.3
  20. DANDY WALTER E., VENTRICULOGRAPHY FOLLOWING THE INJECTION OF AIR INTO THE CEREBRAL VENTRICLES : , 10.1097/00000658-191807000-00002
  21. Ferguson Sherise, Lesniak Maciej S., Percival Bailey and the classification of brain tumors, 10.3171/foc.2005.18.4.8
  22. Bailey O (1985) Genesis of the Percival Bailey-Cushing classification of gliomas. Pediatr Neurosci 12(4–5):261–265
  23. GLOBUS JOSEPH H., SPONGIOBLASTOMA MULTIFORME : A PRIMARY MALIGNANT FORM OF BRAIN NEOPLASM: ITS CLINICAL AND ANATOMIC FEATURES, 10.1001/archneurpsyc.1925.02200140002001
  24. BAILEY PERCIVAL, MEDULLOBLASTOMA CEREBELLI : A COMMON TYPE OF MIDCEREBELLAR GLIOMA OF CHILDHOOD, 10.1001/archneurpsyc.1925.02200140055002
  25. Bailey P, Cushing H (1926) A classification of the tumors of the Glioma group on histogenetic basis with correlated study of prognosis. JB Lipponcott, Philadelphia
  26. Scheithauer Bernd W., Development of the WHO Classification of Tumors of the Central Nervous System: A Historical Perspective, 10.1111/j.1750-3639.2008.00192.x
  27. Canale Dee James, Longo Lawrence D., Harvey Cushing and Pediatric Neurosurgery : , 10.1227/00006123-199010000-00017
  28. Bailey P (1927) Further remarks concerning tumors of the glioma group. Bull Johns Hopkins Hosp 40:354–389
  29. Bradač Gianni B., Büll Udalrich, Fahlbusch Rudolf, Grumme Thomas, Kazner Ekkehard, Kretzschmar Konrad, Lanksch Wolfgang, Meese Wolfang, Schramm Johannes, Steinhoff Harald, Stochdorph Otto, Wende Sigurd, Computed Tomography in Intracranial Tumors, ISBN:9783642966552, 10.1007/978-3-642-96653-8
  30. Bailey P (1933) Intracranial tumors. C.C. Thomas, Springfield
  31. PENFIELD WILDER, THE CLASSIFICATION OF GLIOMAS AND NEUROGLIA CELL TYPES, 10.1001/archneurpsyc.1931.02230100063006
  32. Zülch K. J., Historical development of the classification of brain tumours and the new proposal of the world health organization (WHO), 10.1007/bf01743637
  33. Ohgaki H., Kleihues P., The Definition of Primary and Secondary Glioblastoma, 10.1158/1078-0432.ccr-12-3002
  34. Peiffer Jürgen, Kleihues Paul, Hans-Joachim Scherer (1906-1945), Pioneer in Glioma Research, 10.1111/j.1750-3639.1999.tb00222.x
  35. Scherer H (1940) Cerebral astrocytomas and their derivatives. Am J Cancer 40(2):159–198
  36. Lee Kyu Sang, Choe Gheeyoung, Nam Kyung Han, Seo An Na, Yun Sumi, Kim Kyung Ju, Cho Hwa Jin, Park Sung Hye, Immunohistochemical Classification of Primary and Secondary Glioblastomas, 10.4132/koreanjpathol.2013.47.6.541
  37. SPIEGEL E. A., WYCIS H. T., MARKS M., LEE A. J., Stereotaxic Apparatus for Operations on the Human Brain, 10.1126/science.106.2754.349
  38. Uluç Kutluay, Kujoth Gregory C., Başkaya Mustafa K., Operating microscopes: past, present, and future, 10.3171/2009.6.focus09120
  39. Sachs Ernest, The Problem of the Glioblastomas, 10.3171/jns.1950.7.3.0185
  40. Zülch K (1986) Brain tumours. Their biology and pathology. 3rd edn. Springer, Berlin
  41. Netsky Martin G., August Burton, Fowler William, The Longevity of Patients with Glioblastoma Multiforme, 10.3171/jns.1950.7.3.0261
  42. Delgado-López P. D., Corrales-García E. M., Survival in glioblastoma: a review on the impact of treatment modalities, 10.1007/s12094-016-1497-x
  43. Mut M, Lopes M, Shaffrey M (2005) Lucien J. Rubinstein: enduring contributions to neuro-oncology. Neurosurg Focus 18(4):e8
  44. Roth John G., Elvidge Arthur R., Glioblastoma Multiforme: A Clinical Survey, 10.3171/jns.1960.17.4.0736
  45. Lindquist Christer, Gamma knife radiosurgery, 10.1016/s1053-4296(05)80017-7
  46. Yanagihara Ted K., Saadatmand Heva J., Wang Tony J. C., Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation, 10.1007/s11060-016-2270-2
  47. Hounsfield G. N., Computerized transverse axial scanning (tomography): Part 1. Description of system, 10.1259/0007-1285-46-552-1016
  48. LAUTERBUR P. C., Image Formation by Induced Local Interactions: Examples Employing Nuclear Magnetic Resonance, 10.1038/242190a0
  49. Daumas-Duport Catherine, Scheithauer Bernd, O'Fallon Judith, Kelly Patrick, Grading of astrocytomas: A simple and reproducible method, 10.1002/1097-0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t
  50. Z�lch K. J., Principles of the new World Health Organization (WHO) classification of brain tumors, 10.1007/bf00342596
  51. Buckner Jan C., Brown Paul D., O'Neill Brian P., Meyer Fredric B., Wetmore Cynthia J., Uhm Joon H., Central Nervous System Tumors, 10.4065/82.10.1271
  52. Agnihotri Sameer, Burrell Kelly E., Wolf Amparo, Jalali Sharzhad, Hawkins Cynthia, Rutka James T., Zadeh Gelareh, Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies, 10.1007/s00005-012-0203-0
  53. DANDY WALTER E., REMOVAL OF RIGHT CEREBRAL HEMISPHERE FOR CERTAIN TUMORS WITH HEMIPLEGIA : PRELIMINARY REPORT, 10.1001/jama.1928.02690380007003
  54. Wright James, Chugh Jessey, Wright Christina Huang, Alonso Fernando, Hdeib Alia, Gittleman Haley, Barnholtz-Sloan Jill, Sloan Andrew E., Laser interstitial thermal therapy followed by minimal-access transsulcal resection for the treatment of large and difficult to access brain tumors, 10.3171/2016.8.focus16233
  55. Hervey-Jumper Shawn L., Berger Mitchel S., Maximizing safe resection of low- and high-grade glioma, 10.1007/s11060-016-2110-4
  56. Yong Raymund L., Lonser Russell R., Surgery for Glioblastoma Multiforme: Striking a Balance, 10.1016/j.wneu.2011.06.053
  57. Young R, Jamshidi A, Davis G, Sherman J (2015) Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med 3(9):121
  58. Smets Thibault, Lawson Tévi Morel, Grandin Cécile, Jankovski Aleksandar, Raftopoulos Christian, Immediate post-operative MRI suggestive of the site and timing of glioblastoma recurrence after gross total resection: a retrospective longitudinal preliminary study, 10.1007/s00330-012-2762-1
  59. Mirimanoff René-Olivier, Gorlia Thierry, Mason Warren, Van den Bent Martin J., Kortmann Rolf-Dieter, Fisher Barbara, Reni Michele, Brandes Alba A., Curschmann Jüergen, Villa Salvador, Cairncross Gregory, Allgeier Anouk, Lacombe Denis, Stupp Roger, Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial, 10.1200/jco.2005.04.5963
  60. Patel Dhruv M., Agarwal Nitin, Tomei Krystal L., Hansberry David R., Goldstein Ira M., Optimal Timing of Whole-Brain Radiation Therapy Following Craniotomy for Cerebral Malignancies, 10.1016/j.wneu.2015.03.052
  61. Stupp R., Brada M., van den Bent M. J., Tonn J.- C., Pentheroudakis G., , High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 10.1093/annonc/mdu050
  62. Corso Christopher D., Bindra Ranjit S., Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions, 10.1016/j.semradonc.2016.06.003
  63. Ehrlich P (1913) Address in pathology on chemotherapeutics: scientific principles, methods, and results. Lancet 2(5694):445–451
  64. Krumbhaar E, Krunbhaar H (1919) The blood and bone barrow in yellow cross gas (mustard gas) poisoning. J Med Res 40(3):497–508
  65. KRUMBHAAR E. B., RÔLE OF THE BLOOD AND THE BONE MARROW IN CERTAIN FORMS OF GAS POISONING : I. PERIPHERAL BLOOD CHANGES AND THEIR SIGNIFICANCE, 10.1001/jama.1919.26110010018009f
  66. Fenn John E., Udelsman Robert, First Use of Intravenous Chemotherapy Cancer Treatment: Rectifying the Record, 10.1016/j.jamcollsurg.2010.10.018
  67. Thomas R, Recht L, Nagpal S (2013) Advances in the management of glioblastoma: the role of temozolomide and MGMT testing. Clin Pharmacol 5:1–9
  68. Connors T (1996) Anticancer drug development: the way forward. Oncologist 1(3):180–181
  69. Deeken J. F., Loscher W., The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses, 10.1158/1078-0432.ccr-06-2854
  70. Rubin P., Gash D.M., Hansen J.T., Nelson D.F., Williams J.P., Disruption of the blood-brain barrier as the primary effect of CNS irradiation, 10.1016/0167-8140(94)90413-8
  71. Muldoon Leslie L., Soussain Carole, Jahnke Kristoph, Johanson Conrad, Siegal Tali, Smith Quentin R., Hall Walter A., Hynynen Kullervo, Senter Peter D., Peereboom David M., Neuwelt Edward A., Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check, 10.1200/jco.2006.09.9861
  72. Cohen M. H., Shen Y. L., Keegan P., Pazdur R., FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme, 10.1634/theoncologist.2009-0121
  73. Ashby Lynn S., Smith Kris A., Stea Baldassarre, Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review, 10.1186/s12957-016-0975-5
  74. Westphal M, Hilt D, Bortey E, Delavault P, Olivares R, Warnke P, Whittle I, Jääskeläinen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 5 (2):79–88
  75. Bock Hans Christoph, Puchner Maximilian Josef Anton, Lohmann Frauke, Schütze Michael, Koll Simone, Ketter Ralf, Buchalla Ruediger, Rainov Nikolai, Kantelhardt Sven R., Rohde Veit, Giese Alf, First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience, 10.1007/s10143-010-0280-7
  76. Brem H, Piantadosi S, Burger P.C, Walker M, Selker R, Vick N.A, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold S.C, Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas, 10.1016/s0140-6736(95)90755-6
  77. Borner M., Answering Patients' Needs: Oral Alternatives to Intravenous Therapy, 10.1634/theoncologist.6-suppl_4-12
  78. Liu G, Franssen E, Fitch M I, Warner E, Patient preferences for oral versus intravenous palliative chemotherapy., 10.1200/jco.1997.15.1.110
  79. Brada Michael, Stenning Sally, Gabe Rhian, Thompson Lindsay C., Levy David, Rampling Roy, Erridge Sara, Saran Frank, Gattamaneni Rao, Hopkins Kirsten, Beall Sarah, Collins V. Peter, Lee Siow-Ming, Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma, 10.1200/jco.2009.27.1932
  80. Silber J, Bobola M, Blank A, Chamberlain M (2012) O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems. Biochim Biophys Acta 1826(1):71–82
  81. Prados Michael D., Byron Sara A., Tran Nhan L., Phillips Joanna J., Molinaro Annette M., Ligon Keith L., Wen Patrick Y., Kuhn John G., Mellinghoff Ingo K., de Groot John F., Colman Howard, Cloughesy Timothy F., Chang Susan M., Ryken Timothy C., Tembe Waibhav D., Kiefer Jeffrey A., Berens Michael E., Craig David W., Carpten John D., Trent Jeffrey M., Toward precision medicine in glioblastoma: the promise and the challenges, 10.1093/neuonc/nov031
  82. Davies Angela M., Weinberg Uri, Palti Yoram, Tumor treating fields: a new frontier in cancer therapy : TTFields and cancer therapy, 10.1111/nyas.12112
  83. Taillibert Sophie, Le Rhun Emilie, Chamberlain Marc C., Tumor treating fields : a new standard treatment for glioblastoma?, 10.1097/wco.0000000000000250
  84. Domingo-Musibay Evidio, Galanis Evanthia, What next for newly diagnosed glioblastoma?, 10.2217/fon.15.258
  85. Stupp Roger, Wong Eric T., Kanner Andrew A., Steinberg David, Engelhard Herbert, Heidecke Volkmar, Kirson Eilon D., Taillibert Sophie, Liebermann Frank, Dbalý Vladimir, Ram Zvi, Villano J. Lee, Rainov Nikolai, Weinberg Uri, Schiff David, Kunschner Lara, Raizer Jeffrey, Honnorat Jerome, Sloan Andrew, Malkin Mark, Landolfi Joseph C., Payer Franz, Mehdorn Maximilian, Weil Robert J., Pannullo Susan C., Westphal Manfred, Smrcka Martin, Chin Lawrence, Kostron Herwig, Hofer Silvia, Bruce Jeffrey, Cosgrove Rees, Paleologous Nina, Palti Yoram, Gutin Philip H., NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality, 10.1016/j.ejca.2012.04.011
  86. Wick Wolfgang, Weller Michael, van den Bent Martin, Stupp Roger, Bevacizumab and Recurrent Malignant Gliomas: A European Perspective, 10.1200/jco.2009.26.9027
  87. Desjardins Annick, Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?, 10.1038/nrneurol.2015.127
  88. Gilbert Mark R., Dignam James J., Armstrong Terri S., Wefel Jeffrey S., Blumenthal Deborah T., Vogelbaum Michael A., Colman Howard, Chakravarti Arnab, Pugh Stephanie, Won Minhee, Jeraj Robert, Brown Paul D., Jaeckle Kurt A., Schiff David, Stieber Volker W., Brachman David G., Werner-Wasik Maria, Tremont-Lukats Ivo W., Sulman Erik P., Aldape Kenneth D., Curran Walter J., Mehta Minesh P., A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma, 10.1056/nejmoa1308573
  89. Chinot Olivier L., Wick Wolfgang, Mason Warren, Henriksson Roger, Saran Frank, Nishikawa Ryo, Carpentier Antoine F., Hoang-Xuan Khe, Kavan Petr, Cernea Dana, Brandes Alba A., Hilton Magalie, Abrey Lauren, Cloughesy Timothy, Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma, 10.1056/nejmoa1308345
  90. Wick Wolfgang, Chinot Olivier L., Bendszus Martin, Mason Warren, Henriksson Roger, Saran Frank, Nishikawa Ryo, Revil Cedric, Kerloeguen Yannick, Cloughesy Timothy, Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma, 10.1093/neuonc/now091
  91. Chinot Olivier L., Nishikawa Ryo, Mason Warren, Henriksson Roger, Saran Frank, Cloughesy Timothy, Garcia Josep, Revil Cedric, Abrey Lauren, Wick Wolfgang, Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio, 10.1093/neuonc/now046
  92. Rose S (2011) FDA pulls approval for Avastin in breast cancer. Cancer Discov 1(7):1–2
  93. Kovic Bruno, Xie Feng, Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme, 10.1200/jco.2014.59.7245
  94. Campos B, Olsen L R, Urup T, Poulsen H S, A comprehensive profile of recurrent glioblastoma, 10.1038/onc.2016.85
  95. Sun Hao, Du Shasha, Liao Guixiang, Xie Xiao, Ren Chen, Yuan Ya Wei, Do Glioma Patients Derive Any Therapeutic Benefit From Taking a Higher Cumulative Dose of Temozolomide Regimens? : A Meta-Analysis, 10.1097/md.0000000000000827
  96. Tosoni Alicia, Franceschi Enrico, Poggi Rosalba, Brandes Alba A., Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences, 10.1007/s11864-016-0422-4
  97. Yin An-an, Cheng Jin-xiang, Zhang Xiang, Liu Bo-lin, The treatment of glioblastomas: A systematic update on clinical Phase III trials, 10.1016/j.critrevonc.2013.01.007
  98. clinicaltrials.gov National Library of Medicine (US) Accessed 31 Oct 2016
  99. Tavano Lorena, Muzzalupo Rita, Multi-functional vesicles for cancer therapy: The ultimate magic bullet, 10.1016/j.colsurfb.2016.07.060
  100. Stupp Roger, Hegi Monika E, Mason Warren P, van den Bent Martin J, Taphoorn Martin JB, Janzer Robert C, Ludwin Samuel K, Allgeier Anouk, Fisher Barbara, Belanger Karl, Hau Peter, Brandes Alba A, Gijtenbeek Johanna, Marosi Christine, Vecht Charles J, Mokhtari Karima, Wesseling Pieter, Villa Salvador, Eisenhauer Elizabeth, Gorlia Thierry, Weller Michael, Lacombe Denis, Cairncross J Gregory, Mirimanoff René-Olivier, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, 10.1016/s1470-2045(09)70025-7
  101. Scott Jacob G., Bauchet Luc, Fraum Tyler J., Nayak Lakshmi, Cooper Anna R., Chao Samuel T., Suh John H., Vogelbaum Michael A., Peereboom David M., Zouaoui Sonia, Mathieu-Daudé Hélène, Fabbro-Peray Pascale, Rigau Valérie, Taillandier Luc, Abrey Lauren E., DeAngelis Lisa M., Shih Joanna H., Iwamoto Fabio M., Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older, 10.1002/cncr.27570
  102. Neagu Martha R., Reardon David A., An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors, 10.1007/s11864-015-0371-3
  103. Sampson John H., Mitchell Duane A., Vaccination strategies for neuro-oncology: Table 1., 10.1093/neuonc/nov159
  104. Ardon Hilko, Van Gool Stefaan, Lopes Isabel Spencer, Maes Wim, Sciot Raf, Wilms Guido, Demaerel Philippe, Bijttebier Patricia, Claes Laurence, Goffin Jan, Van Calenbergh Frank, De Vleeschouwer Steven, Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study, 10.1007/s11060-010-0131-y
  105. Schijns Virgil E.J.C., Pretto Chrystel, Devillers Laurent, Pierre Denis, Hofman Florence M., Chen Thomas C., Mespouille Pascal, Hantos Peter, Glorieux Philippe, Bota Daniela A., Stathopoulos Apostolos, First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity, 10.1016/j.vaccine.2015.03.095
  106. Reijneveld J. C., Voest Emile E., Taphoorn Martin J. B., Angiogenesis in malignant primary and metastatic brain tumors, 10.1007/s004150070128
  107. Scaringi C, Enrici R, Minniti G (2013) Combining molecular targeted agents with radiation therapy for malignant gliomas. Onco Targets Ther 6:1079–1095
  108. McGee Mackenzie C., Hamner J. Blair, Williams Regan F., Rosati Shannon F., Sims Thomas L., Ng Catherine Y., Gaber M. Waleed, Calabrese Christopher, Wu Jianrong, Nathwani Amit C., Duntsch Christopher, Merchant Thomas E., Davidoff Andrew M., Improved Intratumoral Oxygenation Through Vascular Normalization Increases Glioma Sensitivity to Ionizing Radiation, 10.1016/j.ijrobp.2009.12.010
  109. Gupta Vinay K., Jaskowiak Nora T., Beckett Michael A., Mauceri Helena J., Grunstein Jeremy, Johnson Randall S., Calvin Douglas A., Nodzenski Edwardine, Pejovic Marija, Kufe Donald W., Posner Mitchell C., Weichselbaum Ralph R., Vascular Endothelial Growth Factor Enhances Endothelial Cell Survival and Tumor Radioresistance : , 10.1097/00130404-200201000-00009
  110. Bolderson E., Richard D. J., Zhou B.-B. S., Khanna K. K., Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair, 10.1158/1078-0432.ccr-09-0096
  111. Rouleau Michèle, Patel Anand, Hendzel Michael J., Kaufmann Scott H., Poirier Guy G., PARP inhibition: PARP1 and beyond, 10.1038/nrc2812
  112. Bryant Helen E., Schultz Niklas, Thomas Huw D., Parker Kayan M., Flower Dan, Lopez Elena, Kyle Suzanne, Meuth Mark, Curtin Nicola J., Helleday Thomas, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, 10.1038/nature03443
  113. Farmer Hannah, McCabe Nuala, Lord Christopher J., Tutt Andrew N. J., Johnson Damian A., Richardson Tobias B., Santarosa Manuela, Dillon Krystyna J., Hickson Ian, Knights Charlotte, Martin Niall M. B., Jackson Stephen P., Smith Graeme C. M., Ashworth Alan, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, 10.1038/nature03445
  114. Powell C., Mikropoulos C., Kaye S.B., Nutting C.M., Bhide S.A., Newbold K., Harrington K.J., Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers, 10.1016/j.ctrv.2010.03.003
  115. Senra J. M., Telfer B. A., Cherry K. E., McCrudden C. M., Hirst D. G., O'Connor M. J., Wedge S. R., Stratford I. J., Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft, 10.1158/1535-7163.mct-11-0278
  116. Bonnet Dominique, Dick John E., Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell, 10.1038/nm0797-730
  117. Galli Rossella, Binda Elena, Orfanelli Ugo, Cipelletti Barbara, Gritti Angela, De Vitis Simona, Fiocco Roberta, Foroni Chiara, Dimeco Francesco, Vescovi Angelo, Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma, 10.1158/0008-5472.can-04-1364
  118. Beier D., Rohrl S., Pillai D. R., Schwarz S., Kunz-Schughart L. A., Leukel P., Proescholdt M., Brawanski A., Bogdahn U., Trampe-Kieslich A., Giebel B., Wischhusen J., Reifenberger G., Hau P., Beier C. P., Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma, 10.1158/0008-5472.can-07-6878
  119. Hegi Monika E., Diserens Annie-Claire, Gorlia Thierry, Hamou Marie-France, de Tribolet Nicolas, Weller Michael, Kros Johan M., Hainfellner Johannes A., Mason Warren, Mariani Luigi, Bromberg Jacoline E.C., Hau Peter, Mirimanoff René O., Cairncross J. Gregory, Janzer Robert C., Stupp Roger, MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma, 10.1056/nejmoa043331
  120. Lathia Justin D., Mack Stephen C., Mulkearns-Hubert Erin E., Valentim Claudia L.L., Rich Jeremy N., Cancer stem cells in glioblastoma, 10.1101/gad.261982.115
  121. Gupta Piyush B., Onder Tamer T., Jiang Guozhi, Tao Kai, Kuperwasser Charlotte, Weinberg Robert A., Lander Eric S., Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening, 10.1016/j.cell.2009.06.034
  122. Qin Li-sen, Jia Pi-feng, Zhang Zhi-qing, Zhang Shi-ming, ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosis, 10.1186/s13046-015-0174-1
  123. Calzolari Alessia, Saulle Ernestina, De Angelis Maria Laura, Pasquini Luca, Boe Alessandra, Pelacchi Federica, Ricci-Vitiani Lucia, Baiocchi Marta, Testa Ugo, Salinomycin Potentiates the Cytotoxic Effects of TRAIL on Glioblastoma Cell Lines, 10.1371/journal.pone.0094438
  124. Pardridge William M., Blood–brain barrier delivery, 10.1016/j.drudis.2006.10.013
  125. Vogelbaum M. A., Aghi M. K., Convection-enhanced delivery for the treatment of glioblastoma, 10.1093/neuonc/nou354
  126. Hynynen K, McDannold N, Vykhodtseva N, Jolesz F (2003) Non-invasive opening of BBB by focused ultrasound. Acta Neurochir Suppl 86:555–558
  127. Choi J.J., Feshitan J.A., Baseri B., Shougang Wang, Yao-Sheng Tung, Borden M.A., Konofagou E.E., Microbubble-Size Dependence of Focused Ultrasound-Induced Blood–Brain Barrier Opening in Mice In Vivo, 10.1109/tbme.2009.2034533
  128. Liu Hao-Li, Hsu Po-Hung, Lin Chung-Yin, Huang Chiun-Wei, Chai Wen-Yen, Chu Po-Chun, Huang Chiung-Yin, Chen Pin-Yuan, Yang Liang-Yo, Kuo John S., Wei Kuo-Chen, Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment, 10.1148/radiol.2016152444
  129. Carpentier A., Canney M., Vignot A., Reina V., Beccaria K., Horodyckid C., Karachi C., Leclercq D., Lafon C., Chapelon J.-Y., Capelle L., Cornu P., Sanson M., Hoang-Xuan K., Delattre J.-Y., Idbaih A., Clinical trial of blood-brain barrier disruption by pulsed ultrasound, 10.1126/scitranslmed.aaf6086
  130. Sarkar Gobinda, Curran Geoffry L., Sarkaria Jann N., Lowe Val J., Jenkins Robert B., Peptide Carrier-Mediated Non-Covalent Delivery of Unmodified Cisplatin, Methotrexate and Other Agents via Intravenous Route to the Brain, 10.1371/journal.pone.0097655
  131. Allen T. M., Drug Delivery Systems: Entering the Mainstream, 10.1126/science.1095833
  132. Peer Dan, Karp Jeffrey M., Hong Seungpyo, Farokhzad Omid C., Margalit Rimona, Langer Robert, Nanocarriers as an emerging platform for cancer therapy, 10.1038/nnano.2007.387
  133. Gutkin Anna, Cohen Zvi R., Peer Dan, Harnessing nanomedicine for therapeutic intervention in glioblastoma, 10.1080/17425247.2016.1200557
  134. Kim Sang-Soo, Harford Joe B., Pirollo Kathleen F., Chang Esther H., Effective treatment of glioblastoma requires crossing the blood–brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine, 10.1016/j.bbrc.2015.06.137
  135. Danhier Fabienne, Messaoudi Khaled, Lemaire Laurent, Benoit Jean-Pierre, Lagarce Frédéric, Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: In vivo evaluation, 10.1016/j.ijpharm.2015.01.051
  136. Bastiancich C., Vanvarenberg K., Ucakar B., Pitorre M., Bastiat G., Lagarce F., Préat V., Danhier F., Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma, 10.1016/j.jconrel.2016.01.054
  137. Hoare Todd R., Kohane Daniel S., Hydrogels in drug delivery: Progress and challenges, 10.1016/j.polymer.2008.01.027
  138. Bastiancich C., Danhier P., Préat V., Danhier F., Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma, 10.1016/j.jconrel.2016.09.034
  139. Vellimana Ananth K., Recinos Violette Renard, Hwang Lee, Fowers Kirk D., Li Khan W., Zhang Yonggang, Okonma Saint, Eberhart Charles G., Brem Henry, Tyler Betty M., Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model, 10.1007/s11060-012-1014-1
  140. Fourniols Thibaut, Randolph Luc D., Staub Aurélie, Vanvarenberg Kevin, Leprince Julian G., Préat Véronique, des Rieux Anne, Danhier Fabienne, Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma, 10.1016/j.jconrel.2015.05.272
  141. MARCHESI F, TURRIZIANI M, TORTORELLI G, AVVISATI G, TORINO F, DEVECCHIS L, Triazene compounds: Mechanism of action and related DNA repair systems, 10.1016/j.phrs.2007.08.003
  142. Perazzoli Gloria, Prados Jose, Ortiz Raul, Caba Octavio, Cabeza Laura, Berdasco Maria, Gónzalez Beatriz, Melguizo Consolación, Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression, 10.1371/journal.pone.0140131
  143. Weller Michael, Stupp Roger, Reifenberger Guido, Brandes Alba A., van den Bent Martin J., Wick Wolfgang, Hegi Monika E., MGMT promoter methylation in malignant gliomas: ready for personalized medicine?, 10.1038/nrneurol.2009.197
  144. Parker N, Khong P, Parkinson J, Howell V, Wheeler H (2015) Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol 5:55
  145. Messaoudi Khaled, Clavreul Anne, Danhier Fabienne, Saulnier Patrick, Benoit Jean-Pierre, Lagarce Frederic, Combined silencing expression of MGMT with EGFR or galectin-1 enhances the sensitivity of glioblastoma to temozolomide, 10.1515/ejnm-2014-0041
  146. Kaina Bernd, Margison Geoffrey P., Christmann Markus, Targeting O 6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy, 10.1007/s00018-010-0491-7
  147. Ramirez Y. P., Mladek A. C., Phillips R. M., Gynther M., Rautio J., Ross A. H., Wheelhouse R. T., Sakaria J. N., Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth, 10.1158/1535-7163.mct-14-0113
  148. Rich Jeremy N., Bigner Darell D., Development of novel targeted therapies in the treatment of malignant glioma, 10.1038/nrd1380
  149. Verschuere Tina, Toelen Jaan, Maes Wim, Poirier Françoise, Boon Louis, Tousseyn Thomas, Mathivet Thomas, Gerhardt Holger, Mathieu Veronique, Kiss Robert, Lefranc Florence, Van Gool Stefaan W., Vleeschouwer Steven De, Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity : Immunological Role of Galectin-1 in Murine Glioma, 10.1002/ijc.28426
  150. Le Mercier Marie, Fortin Shannon, Mathieu Véronique, Kiss Robert, Lefranc Florence, Galectins and Gliomas : Galectins and Gliomas, 10.1111/j.1750-3639.2009.00270.x
  151. Camby Isabelle, Decaestecker Christine, Lefranc Florence, Kaltner Herbert, Gabius Hans-Joachim, Kiss Robert, Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern, 10.1016/j.bbrc.2005.07.037
Bibliographic reference Bianco, John ; Bastiancich, Chiara ; Jankovski, Aleksandar ; des Rieux, Anne ; Préat, Véronique ; et. al. On glioblastoma and the search for a cure: where do we stand?. In: Cellular and Molecular Life Sciences, Vol. 74, no. 13, p. 2451-2466 (2017)
Permanent URL http://hdl.handle.net/2078.1/183343